Immunovant rises as autoimmune drug succeeds in mid-stage trial
Brief: Roivant Reports Positive Initial Phase 2 Results For Batoclimab In Graves’ Disease
Brief: Immunovant Reports Positive Initial Phase 2 Results For Batoclimab In Graves’ Disease
U.S. STOCKS ON THE MOVE-Coinbase Global, Spirit AeroSystems, Crown Castle
U.S. STOCKS ON THE MOVE-Toro, TRACON Pharma, Fulton Financial
U.S. STOCKS ON THE MOVE-Passage Bio, Discover Financial, Alphabet
Immunovant drops after failure of rival's autoimmune therapy
Argenx's market cap takes $6.3 bln hit after failed drug study (updated)
Brief: Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results That Confirm Best-In-Class Potential
Brief: Immunovant - QTRLY Loss Per Share $0.45
Immunovant Inc expected to post a loss of 47 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-American Express, Braze, Engagesmart
U.S. RESEARCH ROUNDUP- JP Morgan, Tesla, Tractor Supply
Brief: Roivant Sciences Ltd. Says May Provide Additional Financing To Immunovant From Time To Time In Equity Investment, Issuer's Debt Securities, Loans
U.S. STOCKS ON THE MOVE-General Electric, Nike, Dell Technologies
U.S. STOCKS ON THE MOVE-Workday, Amazon, Accenture
U.S. STOCKS ON THE MOVE-Bolt Biotherapeutics, Sunnova, Jabil
Immunovant slips after pricing $450 mln equity offering
Brief: Immunovant Announces Pricing Of $450 Million Common Stock Financing